Psilocybin Microdosing on Cognition, Mood and Quality of Life
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age21-40
SponsorYale University
About this trial
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
Eligibility criteria
Qualifiers
No history of psychedelic use
Able to read, speak, and understand English
Able and willing to provide written informed consent, and willing to commit to study protocol
Women of childbearing potential must be on a highly effective birth control method
Disqualifiers
Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment
Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V
Current or past alcohol or substance use disorder per DSM-V
IQ <70 on the Weschler Abbreviated Scale of Intelligence
Trial design
Treatments tested in this trial
- Psliocybin
- Placebo
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yale University
Lead sponsor
Hartford HealthCare
Collaborator
Source ClinicalTrials.gov